Cencora, Inc. (COR)

NYSE: COR · Real-Time Price · USD
241.43
-2.03 (-0.83%)
Feb 21, 2025, 4:00 PM EST - Market closed
-0.83%
Market Cap 46.82B
Revenue (ttm) 303.19B
Net Income (ttm) 1.40B
Shares Out 193.92M
EPS (ttm) 7.02
PE Ratio 34.38
Forward PE 15.35
Dividend $2.20 (0.91%)
Ex-Dividend Date Feb 14, 2025
Volume 1,060,825
Open 241.45
Previous Close 243.46
Day's Range 240.73 - 243.49
52-Week Range 214.77 - 262.26
Beta 0.49
Analysts Buy
Price Target 274.80 (+13.82%)
Earnings Date Feb 5, 2025

About COR

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply ... [Read more]

Sector Healthcare
Founded 2001
Employees 46,000
Stock Exchange NYSE
Ticker Symbol COR
Full Company Profile

Financial Performance

In 2024, Cencora's revenue was $293.96 billion, an increase of 12.12% compared to the previous year's $262.17 billion. Earnings were $1.51 billion, a decrease of -13.53%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for COR stock is "Buy." The 12-month stock price forecast is $274.8, which is an increase of 13.82% from the latest price.

Price Target
$274.8
(13.82% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of ap...

15 days ago - Business Wire

Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) has agreed to the early settlement of certain prepaid variable share forward transactions it had previously entered into ...

Other symbols: WBA
15 days ago - Business Wire

Cencora Reinforces Efforts to Strengthen Pharmaceutical Supply Chain with Expansion of Drug Shortages Mitigation Program

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation...

15 days ago - Business Wire

Cencora (COR) Q1 2025 Earnings Call Transcript

Cencora Inc. (NYSE:COR) Q1 2025 Earnings Conference Call February 5, 2025 8:30 AM ET Company Participants Robert Mauch - President, Chief Executive Officer James Cleary - Executive Vice President, Ch...

16 days ago - Seeking Alpha

Cencora raises 2025 profit forecast on specialty drug demand

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

16 days ago - Reuters

Cencora Reports Fiscal 2025 First Quarter Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billio...

16 days ago - Business Wire

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategi...

Other symbols: HROW
25 days ago - Business Wire

Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth

Seeking Alpha's Quant Valuation and Growth Grades identify 6 blue-chip stocks with extremely high valuations matched against limited operating growth potential. Costco, Cencora, West Pharmaceutical Se...

Other symbols: COSTDHRELMSGSWST
5 weeks ago - Seeking Alpha

Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the ope...

6 weeks ago - Business Wire

Cencora raises annual profit forecast

Drug distributor Cencora raised its annual adjusted profit forecast on Thursday.

7 weeks ago - Reuters

Cencora Completes Acquisition of Retina Consultants of America

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the completion of its previously announced acquisition of Retina Consultants of America (“RCA”), a leading management serv...

7 weeks ago - Business Wire

Cencora Closes $1.8 Billion Senior Notes Offering

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500,000,000 aggregate principal amount of its 4.625% Senior Notes due December 15, ...

2 months ago - Business Wire

Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, announced the launch of Accelerate Pharmacy Solutions, a unified portfolio of solutions designed to help hospital and health s...

2 months ago - Business Wire

Cencora: Competitive Advantages Defined

Cencora is a 'super cash cow' with high capital turnover and low margins, generating substantial free cash flow from its competitive advantages. COR's business model thrives on low-cost operations, en...

2 months ago - Seeking Alpha

Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the “2027 Notes”)...

2 months ago - Business Wire

Cencora to Host Inaugural Product Showcase

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, will host its inaugural Product Showcase, an event that will provide increased visibility into the company's portfolio of solu...

3 months ago - Business Wire

Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings

On Wednesday, Cencora, Inc.'s COR fourth-quarter 2024 sales increased 14.7% to $79.1 billion, beating the consensus of $77.65 billion.

3 months ago - Benzinga

Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript

Cencora, Inc. (NYSE:COR) Q4 2024 Earnings Call Transcript November 6, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR Bob Mauch - President and CEO Laz Krikorian - SVP and CAO C...

3 months ago - Seeking Alpha

Cencora to buy Retina Consultants of America for $4.6 bln

Drug distributor Cencora said on Wednesday it would acquire Retina Consultants of America (RCA) for $4.6 billion in cash, gaining access to its network of eye specialists.

3 months ago - Reuters

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Reve...

3 months ago - Business Wire

Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America (“RCA”), a leading management ser...

3 months ago - Business Wire

Cencora Expands Enterprise Leadership Team with Two Senior Appointments

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice Pr...

3 months ago - Business Wire

Dividend Aristocrats Of The Future - Part 3

This is the final group of 10 companies scheduled to reach dividend aristocrat status, sometime over the next five years. There are a variety of companies listed, some of whom may not be able to reach...

Other symbols: AIZCOSTCSXDUKKRSGSRE
4 months ago - Seeking Alpha

Cencora Announces Date and Time for Fourth Quarter Fiscal 2024 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2024 on Wednesday, November 6, 2024, prior to the op...

5 months ago - Business Wire

Cencora Supports Pharmaceutical Supply Chain Education with Two New Programs for Health System Pharmacy Residents

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora (formerly AmerisourceBergen), a global healthcare company, announced its two latest pharmacy education initiatives that are designed to equip health system ...

5 months ago - Business Wire